R&D | May 25, 2026
Lilly brings heavy oncology firepower to ASCO with plenary data across cancers
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
Access to genomic testing, not therapy cost, is the biggest challenge
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
